Efficacy of Early Infliximab Treatment for Pediatric Crohn’s Disease: A Three-year Follow-up
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose: To investigate the efficacy of early infliximab use and to follow the progress of pediatric cases of Crohn’s disease for 3 years. Methods: We reviewed the medical records of 28 pediatric patients who had been treated with infliximab for Crohn’s disease. Eighteen patients (the ‘top-down’ group) received infliximab and azathioprine for induction and maintenance therapy for the first year, and then were treated with azathioprine for 2 additional years. Ten patients who were refractory to conventional therapy were categorized in the ‘step-up’ group. All patients were followed for at least 36 months. Treatment efficacy was assessed by the relapse rate using the pediatric Crohn’s disease activity index (PCDAI) score in each group at 12, 24, and 36 months. Blood samples were available from 10 patients, and were used to assess antibody to infliximab (ATI). Results: The relapse rate in ‘top-down’ group was lower than that in ‘step-up’ group at 1, 2, and 3 years. But, just the relapse rate at the 2 years was significantly different. At 3 years, the relapse rate according to different characteristic variables (sex, age at diagnosis, involvement, PCDAI at diagnosis) was not significantly different. Only one patient treated with infliximab had an adverse event, consisting of dyspnea and tachycardia. ATI was not detected in the blood samples from 10 patients. Conclusion: Early induction with infliximab at diagnosis (‘top-down’ therapy) is effective for reducing the relapse rate compared to conventional therapies in pediatric Crohn’s disease possibly for up to 3 years.
Abstract
Purpose: To investigate the efficacy of early infliximab use and to follow the progress of pediatric cases of Crohn’s disease for 3 years. Methods: We reviewed the medical records of 28 pediatric patients who had been treated with infliximab for Crohn’s disease. Eighteen patients (the ‘top-down’ group) received infliximab and azathioprine for induction and maintenance therapy for the first year, and then were treated with azathioprine for 2 additional years. Ten patients who were refractory to conventional therapy were categorized in the ‘step-up’ group. All patients were followed for at least 36 months. Treatment efficacy was assessed by the relapse rate using the pediatric Crohn’s disease activity index (PCDAI) score in each group at 12, 24, and 36 months. Blood samples were available from 10 patients, and were used to assess antibody to infliximab (ATI). Results: The relapse rate in ‘top-down’ group was lower than that in ‘step-up’ group at 1, 2, and 3 years. But, just the relapse rate at the 2 years was significantly different. At 3 years, the relapse rate according to different characteristic variables (sex, age at diagnosis, involvement, PCDAI at diagnosis) was not significantly different. Only one patient treated with infliximab had an adverse event, consisting of dyspnea and tachycardia. ATI was not detected in the blood samples from 10 patients. Conclusion: Early induction with infliximab at diagnosis (‘top-down’ therapy) is effective for reducing the relapse rate compared to conventional therapies in pediatric Crohn’s disease possibly for up to 3 years.
참고문헌 (28)
- Cosnes J, "Long-term evolution of disease behavior of Crohn's disease", Inflamm Bowel Dis, 8, pp.244~250 (2002)
- Solberg IC, "Clinical course in Crohn's disease: results of a Norwegian population-based ten-year follow-up study", Clin Gastroenterol Hepatol, 5, pp.1430~1438 (2007)
- Munkholm P, "Disease activity courses in a regional cohort of Crohn's disease patients", Scand J Gastroenterol, 30, pp.699~706 (1995)
- Xavier RJ, "Unravelling the pathogenesis of inflammatory bowel disease", Nature, 448, pp.427~434 (2007)
- Van Assche G, "The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: special situations", J Crohns Colitis, 4, pp.63~101 (2010)
- Lichtenstein GR, "Management of Crohn's disease in adults", Am J Gastroenterol, 104, pp.465~483 (2009)
- Kozuch PL, "General principles and pharmacology of biologics in inflammatory bowel disease", Gastroenterol Clin North Am, 35, pp.757~773 (2006)
- Hanauer SB, "Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial", Lancet, 359, pp.1541~1549 (2002)
- Peyrin-Biroulet L, "Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials", Clin Gastroenterol Hepatol, 6, pp.644~653 (2008)
- 김세희, "한국인 크론병에 대한 Infliximab의 효과", 대한소화기학회지, 54(2), pp.108~116 (2009), 대한소화기학회
- Hyams JS, "Use of infliximab in the treatment of Crohn's disease in children and adolescents", J Pediatr, 137, pp.192~196 (2000)
- Kugathasan S, "Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease", Am J Gastroenterol, 95, pp.3189~3194 (2000)
- Hyams JS, "Long- term outcome of maintenance infliximab therapy in children with Crohn's disease", Inflamm Bowel Dis, 15, pp.816~822 (2009)
- Kim MJ, "Infliximab therapy in children with Crohn's disease: a one-year evaluation of efficacy comparing 'top-down' and 'step-up' strategies", Acta Paediatr, 100, pp.451~455 (2011)
- 이지혁, "Efficacy of early treatment with infliximab in pediatric Crohn’s disease", WORLD JOURNAL OF GASTROENTEROLOGY, 16(14), pp.1776~1781, W J G PRESS
- 이지현, "Infliximab: 불응성 크론병 치료법으로서의 유용성과 Top-down 관해 유도 요법으로서의 가능성", Pediatric Gastroenterology, Hepatology & Nutrition, 11(1), pp.28~35 (2008), 대한소아소화기영양학회
- IBD Working Group of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition, "Inflammatory bowel disease in children and adolescents: recommendations for diagnosis--the Porto criteria", J Pediatr Gastroenterol Nutr, 41, pp.1~7 (2005)
- Hyams J, "Evaluation of the pediatric Crohn disease activity index: a prospective multicenter experience", J Pediatr Gastroenterol Nutr, 41, pp.416~421 (2005)
- Adişen E, "Anti-infliximab antibody status and its relation to clinical response in psoriatic patients: A pilot study", J Dermatol, 37, pp.708~713 (2010)
- Van Limbergen J, "Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease", Gastroenterology, 135, pp.1114~1122 (2008)
- 최기돈, "크론병에서 Infliximab 치료의 효과와 안전성 - 단일 기관에서의 경험", 대한소화기학회지, 46(1), pp.48~55 (2005), 대한소화기학회
- Colombel JF, "Infliximab, azathioprine, or combination therapy for Crohn's disease", N Engl J Med, 362, pp.1383~1395 (2010)
- Baldassano R, "Infliximab (REMICADE) therapy in the treatment of pediatric Crohn's disease", Am J Gastroenterol, 98, pp.833~838 (2003)
- Stephens MC, "Safety and steroid-sparing experience using infliximab for Crohn's disease at a pediatric inflammatory bowel disease center", Am J Gastroenterol, 98, pp.104~111 (2003)
- Elliott MJ, "Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis", Lancet, 344, pp.1125~1127 (1994)
- 좌윤정, "크론병에서 Infliximab 치료에 의해 발생한 건선 1예", 대한소화기학회지, 56(5), pp.324~328 (2010), 대한소화기학회
- So Young Na, "Biological Therapy for Inflammatory Bowel Disease in Children", Pediatric Gastroenterology, Hepatology & Nutrition, 15(1), pp.13~18 (2012), 대한소아소화기영양학회
- 김미진, "Change in the treatment strategy for pediatric Crohn’s disease", Korean Journal of Pediatrics, 53(9), pp.830~833 (2010), 대한소아과학회